4 Scopus citations


Molecules involved in drug resistance can be targeted for better therapeutic efficacies. Research on midkine (MDK) has escalated in the last few decades, which affirms a positive correlation between disease progression and MDK expression in most cancers and indicates its association with multi-drug resistance in cancer. MDK, a secretory cytokine found in blood, can be exploited as a potent biomarker for the non-invasive detection of drug resistance expressed in various cancers and, thereby, can be targeted. We summarize the current information on the involvement of MDK in drug resistance, and transcriptional regulators of its expression and highlight its potential as a cancer therapeutic target.

Original languageEnglish
Article number8739
JournalInternational journal of molecular sciences
Issue number10
StatePublished - May 2023


  • cancer targeting
  • drug resistance
  • midkine
  • transcriptional regulators


Dive into the research topics of 'Role of Midkine in Cancer Drug Resistance: Regulators of Its Expression and Its Molecular Targeting'. Together they form a unique fingerprint.

Cite this